NASDAQ$JANX
Janux Therapeutics Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Janux Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024, highlighting positive Phase 1 clinical trial data for JANX007 and a significant increase in cash and cash equivalents.
Janux Therapeutics had an exceptional year in 2024, demonstrating substantial clinical activity with JANX007 and significantly strengthening its financial position with $1.03 billion in cash, cash equivalents, and short-term investments. The company reported a net loss of $20.2 million for the quarter, with research and development expenses increasing to $20.8 million.
- Positive updated interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer was presented in December 2024, showing high PSA response rates and encouraging anti-tumor activity.
- Janux reported $1.03 billion in cash, cash equivalents, and short-term investments as of December 31, 2024, a substantial increase from the previous year.
- Research and development expenses for the quarter increased to $20.8 million from $12.2 million in the same period last year, reflecting ongoing clinical programs.
- The company plans to host an R&D Day in 2025 to disclose new programs moving toward the clinic and provide updates on JANX007 and JANX008 data.
Headline financials
Revenue & EPS history
Janux · Revenue · Quarterly
$0
Revenue by segment
Janux · $1.06M total across 1 segment · Q2 2023
- Collaboration revenue$1.06M-55.3%100.0%
Forward guidance
Janux Therapeutics anticipates continued clinical development for JANX007 and JANX008, with updates expected in 2025. The company plans to host an R&D Day in 2025 to introduce new pipeline programs.
Tailwinds
- Enrollment for JANX007 and JANX008 clinical trials is ongoing.
- Anticipated R&D Day in 2025 to disclose new programs moving toward the clinic.
- Update on JANX007 and JANX008 data expected in 2025.
- Well-positioned to execute on clinical plans due to substantial cash runway.
- Bringing new programs towards the clinic that could provide substantial value.
Headwinds
- Compounds that appear promising in early research may not demonstrate safety and/or efficacy in later preclinical studies or clinical trials.
- Risk that Janux may not obtain approval to market its product candidates.
- Uncertainties associated with performing clinical trials, regulatory filings, and applications.
- Risks associated with reliance on third parties to successfully conduct clinical trials.
- Risks associated with reliance on outside financing to meet capital requirements.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
+0.6%
Avg return
Earnings day
-1.5%
Avg return
5 days after
-5.5%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+14.6%
Q3 2022
Best reaction
-11.0%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | -1.4% | -8.8% | |
| Q4 2025 | -1.4% | +4.0% | -4.5% | |
| Q3 2025 | +3.9% | +4.8% | -40.1% | |
| Q1 2025 | -0.8% | +3.8% | -2.8% | |
| Q4 2024 | +2.7% | -1.6% | -9.1% | |
| Q3 2024 | -1.9% | -2.9% | +17.6% | |
| Q2 2024 | -1.1% | -0.8% | +11.8% | |
| Q1 2024 | -11.0% | -21.3% | -31.5% | |
| Q4 2023 | -1.6% | -1.7% | -13.5% | |
| Q3 2023 | +5.9% | -3.4% | +50.7% | |
| Q2 2023 | +5.1% | +4.3% | -11.6% | |
| Q1 2023 | +1.1% | -7.0% | -3.5% | |
| Q4 2022 | -2.5% | -4.7% | -4.9% | |
| Q3 2022 | +14.6% | +5.3% | -9.8% | |
| Q2 2022 | +1.0% | -4.9% | -3.2% | |
| Q1 2022 | +6.1% | +13.7% | +10.0% | |
| Q4 2021 | -6.0% | -3.5% | -17.1% | |
| Q3 2021 | -1.6% | -7.4% | -23.9% | |
| Q2 2021 | -1.0% | -3.8% | -9.9% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro